作者
Daniel O Clegg, Domenic J Reda, Michael H Weisman, Warren D Blackburn, John J Cush, Grant W Cannon, Maren L Mahowald, H Ralph Schumacher Jr, Thomas Taylor, Elly Budiman‐Mak, Miriam R Cohen, Frank B Vasey, Michael E Luggen, Edwin Mejias, Stuart L Silverman, Rama Makkena, F Paul Alepa, Joel Buxbaum, Clair M Haakenson, Richard H Ward, BJ Manaster, Robert J Anderson, John R Ward, William G Henderson
发表日期
1996/12
期刊
Arthritis & Rheumatism
卷号
39
期号
12
页码范围
2004-2012
出版商
John Wiley & Sons, Inc.
简介
Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active ankylosing spondylitis (AS) that is not controlled with nonsteroidal antiinflammatory drug therapy.
Methods. Two hundred sixty‐four patients with AS were recruited from 15 clinics, randomized (double‐blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on morning stiffness, back pain, and physician and patient global assessments.
Results. While longitudinal analysis revealed a trend favoring SSZ in the middle of treatment, no difference was seen at the end of treatment. Response rates were 38.2% for SSZ and 36.1% for placebo (P = 0.73). The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). AS patients with associated peripheral arthritis showed improvement that favored SSZ (P = 0.02 …
引用总数
学术搜索中的文章
DO Clegg, DJ Reda, MH Weisman, WD Blackburn… - Arthritis & Rheumatism, 1996